Zomedica Pharma

69 articles with Zomedica Pharma

• Zomedica Appoints Larry Heaton as President and Announces CEO Succession Plan

  10/4/2021

  Zomedica Corp., a veterinary health company creating point-of-care diagnostic and therapeutic products for companion animals, announced that Larry Heaton has been appointed President effective October 1, 2021.

• Zomedica Provides Corporate Update - July 06, 2021

  7/6/2021

  Zomedica Corp., a veterinary health company creating point-of-care diagnostics products for dogs and cats, provided the following corporate update:

• Zomedica Hires Vice President Business Development to Lead Acquisition and Licensing Efforts

  5/17/2021

  Former Elanco Animal Health, Johnson & Johnson, Intuitive Surgical, and Enteromedics Business Development Executive Joins Team to Support Growth Opportunities

• Zomedica Announces First Quarter 2021 Financial Results

  5/12/2021

  Zomedica Corp., a veterinary health company creating point-of-care diagnostics products for dogs and cats, reported consolidated financial results for the three months ended March 31, 2021.

• Zomedica Announces First Commercial Sale of Its Truforma® Platform

  3/16/2021

  Zomedica Corp., a veterinary health company creating point-of-care diagnostics products for dogs and cats, yesterday recorded the first veterinarian sale of TRUFORMA® and officially entered commercialization.

• Zomedica Retires Preferred Shares TRUFORMA® Progressing Toward Commercialization

  3/8/2021

  Zomedica Corp., a veterinary health company creating point-of-care diagnostics products for dogs and cats, announced that it has effected the exchange of all of its outstanding Series 1 Preferred Shares for its common shares and that it continues to progress with its planned commercialization of its TRUFORMA® platform.

• Zomedica Corp. Announces Year End 2020 Financial Results

  2/26/2021

  Zomedica Corp., a veterinary health company creating point-of-care diagnostics products for dogs and cats, reported consolidated financial results for the year ended December 31, 2020.

• Zomedica Corp. Announces Closing of $173.5 Million Bought Deal

  2/11/2021

  Zomedica Corp. (NYSE American: ZOM), (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, today announced that the closing of its previously announced public offering of 91,315,790 common shares of Zomedica, at a price to the public of $1.90 per share, less underwriting discounts and commissions.

• Zomedica Corp. Increases Previously Announced Bought Deal Offering of Common Shares to $173.5 Million

  2/9/2021

  Zomedica Corp. announced that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 91,315,790 common shares of Zomedica, at a price to the public of $1.90 per share, less underwriting discounts and commissions.

• Zomedica Corp. Announces $25.0 Million Bought Deal Offering of Common Shares

  2/8/2021

  Zomedica Corp. announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 13,157,895 common shares of Zomedica, at a price to the public of $1.90 per share, less underwriting discounts and commissions.

• Zomedica Completes Internal “Launch Team” for Upcoming TRUFORMA™ Commercialization

  12/7/2020

  Zomedica Corp., a veterinary health company creating point-of-care diagnostics products for dogs and cats, announced that, with the hiring of Debra Rock to lead the Company’s Marketing Department, its internal commercial leadership team is complete.

• Zomedica Sets March 30, 2021 as Expected Commercialization Date for TRUFORMA™Certain assays under development are believed to be the first ever for use at the point-of-care and the first ever available in veterinary medicine

  11/13/2020

  Zomedica Corp., a veterinary health company creating point-of-care diagnostics products for dogs and cats, announced that it expects to begin commercialization of its TRUFORMA™ point-of-care diagnostic platform on March 30, 2021.

• Zomedica Announces Third Quarter 2020 Financial Results

  11/12/2020

  Zomedica Corp. reported consolidated financial results for the third quarter ended September 30, 2020. Amounts, unless specified otherwise, are expressed in U.S. dollars and presented under accounting principles generally accepted in the United States of America.

• Zomedica Announces Name Change

  10/2/2020

  Zomedica Corp. (formerly Zomedica Pharmaceuticals Corp.) (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostic products for companion animals, announced that it has changed its legal name to Zomedica Corp. The Company’s stock trading symbol will remain as ZOM on the NYSE American and the shares will begin trading under the new name effective on October 5, 2020. The Company’s board

• Zomedica Announces Shareholder Meeting Voting Results

  9/25/2020

  Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for companion animals, today announced the voting results of its 2020 Annual and Special Virtual-Only Meeting of Shareholders (the “ Meeting”). At the Meeting, the Company’s shareholders approved the following proposals: Election of Jeffrey Rowe, Robert Cohen, Johnny D. Powers, Rodney

• Zomedica Announces Presentation at Upcoming H.C. Wainwright Virtual Global Investment Conference

  9/10/2020

  - Zomedica Pharmaceuticals Corp. (NYSE American: ZOM), a veterinary health company creating point-of-care diagnostics products for companion animals, announced today that Robert Cohen, Interim Chief Executive Officer, and Stephanie Morley, President and Chief Medical Officer, will present at the upcoming H.C. Wainwright Virtual Global Investment Conference. The presentation is scheduled for September 14, 2020 at 4:00 pm ET. The slides to be p

• Zomedica to Develop Gastrointestinal Testing Panel for TRUFORMA™Three new assays to be added to the five assays currently under development

  9/8/2020

  to target diagnosis of canine gastrointestinal issues. The new assays are in addition to the initial five assays currently under development, including panels for adrenal and thyroid testing, for TRUFORMA™, Zomedica's point-of-care veterinary diagnostic platform.

• Zomedica Announces Letter From Robert Cohen, Interim CEO, Made Available to Shareholders in Connection With Annual and Special Virtual-Only Meeting

  8/27/2020

  Zomedica Pharmaceuticals Corp. announced that the following letter from Robert Cohen, Interim Chief Executive Officer, has been made available to shareholders.

• Zomedica Announces Management Change

  8/3/2020

  Zomedica Pharmaceuticals Corp., a veterinary health company, announced that Shameze Rampertab has resigned as Chief Financial Officer and member of the Board of Directors, effective August 14, 2020.

• Successful Remote Installation of TRUFORMA™Permits Validation and Pilot Program Progress During COVID-19 Restrictions

  7/21/2020

  Zomedica Pharmaceuticals Corp., a veterinary health company, announced that, in response to the COVID-19 crisis, it successfully implemented its first completely remote installations of TRUFORMA™, the Company's inaugural point-of-care diagnostic device. Remote installation has enabled Zomedica to proceed with validation testing with its clinical College of Veterinary Medicine partners at Auburn, Mississippi State, and Purdue Universities.